PROVECTUS BIOPHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 69.50% for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-12.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2015-03-12

PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2013 was 69.50%, a 9.62% increase from fiscal 2012.
PROVECTUS BIOPHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2012 was 63.40%.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month
2013-12-31	69.50% 10-K · filed 2015-03-12
2012-12-31	63.40% 10-K · filed 2014-03-13